Skip to main content

Quoin Pharmaceuticals, Ltd.

For the period ended Sep 30, 2025. Filed Nov 6, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 6, 2025

QNRX$3.91+7.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Table of Contents

INDEX

Page
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS1
PART I-FINANCIAL INFORMATION3
​
Item 1. Financial Statements.3
​
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.18
​
Item 3. Quantitative and Qualitative Disclosures About Market Risk.26
​
Item 4. Controls and Procedures.27
​
PART II-OTHER INFORMATION28
​
Item 1. Legal Proceedings.28
​
Item 1A. Risk Factors.28
​
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.31
​
Item 3. Defaults Upon Senior Securities.31
​
Item 4. Mine Safety Disclosures.31
​
Item 5. Other Information.31
​
Item 6. Exhibits.32
​
SIGNATURES33

GENERAL INFORMATION

Unless otherwise indicated or the context otherwise requires, all references in this Quarterly Report on Form 10-Q (the “Quarterly Report”) to the terms “Quoin,” “Quoin Ltd.,” the “Company,” “us,” “we”, “our” and the “Registrant” refer to Quoin Pharmaceuticals Ltd., an Israeli company, and its consolidated subsidiaries. In this Quarterly Report, the U.S. Securities and Exchange Commission is referred to as the “SEC”, the Securities Act of 1933, as amended, is referred to as the “Securities Act” and the Securities Exchange Act of 1934, as amended, is referred to as the “Exchange Act.”

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.